- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02625857
Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer
August 8, 2019 updated by: Janssen Research & Development, LLC
An Open-Label, Phase 1 Study of the Safety and Immunogenicity of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Subjects With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to find and evaluate the recommended Phase 2 dose (RP2D) of JNJ-64041809, a live attenuated double deleted (LADD) Listeria monocytogenes (bacteria in which two virulence genes, which encode molecules that help cause disease, have been removed) when administered intravenously to participants with metastatic castration-resistant prostate cancer (mCRPC).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a first-in-human (FIH), Phase 1, open-label, multicenter and 2-part study.
The Part 1 of study will be Dose Escalation phase to determine the recommended Phase 2 dose (RP2D) based on safety and pharmacodynamic assessments and Part 2 will be Dose Expansion Phase to evaluate 2 expansion cohorts (Cohort 2A and 2B) after the RP2D for JNJ-64041809 is determined in Part 1.
The study will consist of a Screening Period (from signing of informed consent until immediately before the first dose), an open-label Treatment Period (from the first dose of study drug until the End-of-Treatment Visit); and a Post treatment Follow-up Period (after the End-of Treatment Visit until study discontinuation).
Participants will be primarily evaluated for RP2D.
Participants safety will be evaluated throughout the study.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States
-
-
Maryland
-
Baltimore, Maryland, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Wisconsin
-
Madison, Wisconsin, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the prostate with progressive metastatic disease which, in the opinion of the investigator, requires initiation of new treatment. The assessment of disease progression can be based on either PSA rise, new or progressive soft tissue disease (based on computed tomography [CT] or magnetic resonance imaging [MRI] scans), or new or progressive bony disease based on radionuclide bone scan or 18F-sodium fluoride positron emission tomography/computed tomography [NaF PET/CT] scans). Participants being considered for Cohort 2B must, in addition, have primary or metastatic lesions amenable to tumor biopsies
- Must have received at least 2 prior approved therapies
- Ongoing androgen depletion therapy with a Gonadotropin Releasing Hormone analog or inhibitor, or orchiectomy (surgical or medical castration)
- Serum testosterone levels less than (<) 50 nanogram per deciliter (ng/dL) determined within 4 weeks prior to start of study drug
- For participants previously treated with first generation anti-androgens (ie, flutamide, nilutamide, or bicalutamide), discontinuation of flutamide or nilutamide therapy must occur greater than (>) 4 weeks (>6 weeks for bicalutamide) prior to start of study drug with no evidence of an anti-androgen withdrawal response (no decline in serum PSA)
Exclusion Criteria:
- Untreated brain metastases. Participants must have completed treatment for brain metastasis, and be neurologically stable off steroids, for at least 28 days prior to first dose of study drug
- Untreated spinal cord compression
- History of listeriosis or vaccination with a listeria-based vaccine or prophylactic vaccine (example influenza, pneumococcal, diphtheria, tetanus, and pertussis [dTP/dTAP]) within 28 days of study treatment
- Known allergy to both penicillin and trimethoprim/sulfamethoxazole. Participants who are allergic to only one of these antibiotics are allowed to enroll
- Concurrent treatment with anti -Tumor necrosis factor (TNF) alpha therapies, systemic corticosteroids (prednisone dose >10 mg per day or equivalent) or other immune suppressive drugs within the 2 weeks prior to Screening. Steroids that are topical, inhaled, nasal (spray), or ophthalmic solution are permitted
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Cohort 1A and 1B
JNJ-64041809 will be administered intravenously (IV) once every 21 days.
|
JNJ-64041809 will be administered IV at a lower dose in Cohort 1A (1x10^8 colony forming units [CFU]) and at a higher dose in Cohort 1B (1x10^9 CFU).
|
Experimental: Dose Cohort 2A and 2B
JNJ-64041809 will be administered intravenously (IV) once every 21 days.
|
JNJ-64041809 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Incidence of Dose-limiting-toxicity (DLT)
Time Frame: first 21 days after the first infusion
|
Percentage of Participants who Experienced DLT will be evaluated.
The DLT dose level is defined as an unacceptable level of toxicity as evidenced by a DLT rate of greater than or equal to (>=) 33 percent (%).
|
first 21 days after the first infusion
|
Part 2: Antigen-specific T-cell Response
Time Frame: up to 1 year
|
Biomarker studies will be performed to evaluate immune responses to the vaccine after the first intravenous (IV) immunization.
|
up to 1 year
|
Part 1 and Part 2: Incidence of Adverse Events (AEs)
Time Frame: From signing of informed consent form to 30 days after last dose of study drug
|
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Incidence was defined as the number of participants who experienced an adverse event within their period of participation in this study.
Incidence of adverse events will be assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE).
|
From signing of informed consent form to 30 days after last dose of study drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 and Part 2: Objective Response Rate (ORR)
Time Frame: Baseline up to 30 days after last dose of study drug
|
Objective response rate is defined as the percentage of participants who achieve complete response (CR) or partial response (PR), as assessed by the investigator.
|
Baseline up to 30 days after last dose of study drug
|
Part 1 and Part 2: Duration of Response (DOR)
Time Frame: Baseline up to 30 days after last dose of study drug
|
Duration of response will be calculated from the date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death.
|
Baseline up to 30 days after last dose of study drug
|
Part 1 and Part 2: Progression-free Survival (PFS)
Time Frame: Baseline up to 30 days after last dose of study drug
|
Progression-free survival is defined as the duration from the date of first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death, whichever comes first.
|
Baseline up to 30 days after last dose of study drug
|
Part 1 and Part 2: Time to Prostate Specific Antigen (PSA) progression (TTPP)
Time Frame: Baseline up to 30 days after last dose of study drug
|
Time to PSA progression is measured from the date of first dose of study drug until the date of PSA progression according to the Prostate Cancer Clinical Trials Working Group (PCWG2) criteria.
|
Baseline up to 30 days after last dose of study drug
|
Part 1 and Part 2: Blood Culture Assessment of JNJ-64041809
Time Frame: Periodically during treatment and up to one year after End of Treatment (EOT) visit
|
This assessment will include the reporting of surveillance blood cultures (peripherally drawn, and through venous access device [if applicable]) for 1 year after the completion of JNJ-64041809 therapy.
|
Periodically during treatment and up to one year after End of Treatment (EOT) visit
|
Part 1 and Part 2: Shedding Profile of JNJ-64041809 From Cultured Samples of Feces, Urine, and Saliva
Time Frame: During cycle 1 (up to 21 days of treatment period) and at EOT visit (within 30 days after last dose)
|
The shedding of JNJ-64041809 will be studied in cultures of (1) feces by stool or rectal swab, (2) urine samples, and (3) saliva samples.
|
During cycle 1 (up to 21 days of treatment period) and at EOT visit (within 30 days after last dose)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW Jr. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7. doi: 10.1073/pnas.0406035101. Epub 2004 Sep 13.
- Le DT, Dubenksy TW Jr, Brockstedt DG. Clinical development of Listeria monocytogenes-based immunotherapies. Semin Oncol. 2012 Jun;39(3):311-22. doi: 10.1053/j.seminoncol.2012.02.008.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 10, 2015
Primary Completion (Actual)
July 3, 2018
Study Completion (Actual)
July 3, 2018
Study Registration Dates
First Submitted
December 7, 2015
First Submitted That Met QC Criteria
December 7, 2015
First Posted (Estimate)
December 9, 2015
Study Record Updates
Last Update Posted (Actual)
August 9, 2019
Last Update Submitted That Met QC Criteria
August 8, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR107668
- 64041809PCR1001 (Other Identifier: Janssen Research & Development, LLC)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms, Castration-Resistant
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
Nuvation Bio Inc.WithdrawnProstate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Castrate Resistant Prostate Cancer | Cancer of Prostate | Castration Resistant Prostatic Cancer | Castration Resistant Prostatic NeoplasmsUnited States
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Arcus Biosciences, Inc.Gilead SciencesActive, not recruitingProstatic Neoplasms, Castration-Resistant | Prostatic Cancer, Castration-Resistant | Castration Resistant Prostatic Neoplasms | Androgen-Resistant Prostatic NeoplasmsUnited States, Canada
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingProstate Cancer | Refractory Cancer | Castration Resistant Prostatic CancerUnited States
-
University of California, San FranciscoMerck Sharp & Dohme LLCCompletedMetastatic Prostate Cancer | Castration Resistant Prostatic CancerUnited States
Clinical Trials on JNJ-64041809 (Cohort 1A and 1B)
-
Janssen Research & Development, LLCTerminatedCarcinoma, Non-Small-Cell LungUnited States
-
Janssen Cilag N.V./S.A.CompletedHealthy VolunteersUnited Kingdom
-
Eli Lilly and CompanyCompletedMalignant MelanomaUnited States
-
BiogenCompletedRelapsing Remitting Multiple SclerosisPortugal
-
BiogenAMS Advanced Medical Services GmbHCompletedMultiple Sclerosis, Relapsing-RemittingGermany
-
BayerNovartis Pharmaceuticals; Biogen; EPID Research; Merck Serono Europe LtdCompleted
-
Per PfeifferCompletedFirst-line Treatment for Patients With Non-resectable Gastric Cancer or Cancer of the Esophagus orDenmark
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers Squibb; Boehringer IngelheimCompletedLung Cancer | Non-small Cell Lung Cancer (NSCLC)United States
-
RasCal Therapeutics, Inc.RecruitingGlioblastoma | Pancreatic Cancer | Lung Cancer | Colon Cancer | Advanced Malignant Solid Neoplasm | RAS MutationUnited States
-
BiogenWithdrawnRelapsing Multiple Sclerosis